Synoste

Exit

There are millions of people across the globe suffering from “bone deformities” e.g., limbs or bones of different lengths or scoliosis of their spine. A range of factors can cause these defects: traumatic injury, infections, cancers, and congenital abnormalities. For patients, the deformity may be painful to live with, but the social and psychological stigma can be devastating and can completely wreck their quality of life.

Synoste-ECU

These patients have only a limited range of very painful and inconvenient treatment options – stressful for the patient and their families. For patients with deformed limbs, the most widely used treatment remains limb lengthening with external fixation. While the fixator itself is comparatively cheap, it must be worn for many months, it pierces the patient’s skin and is extremely cumbersome, uncomfortable, and complication prone. The high rate of complications and long sick leaves result in high total treatment costs.

We have used our engineering competencies in the management of smart materials and wireless electronics to create a true disruptive change in treating the above-mentioned patient group. Our first product will be a complete leg lengthening solution. The Synoste Nitinail is an internally implantable device that offers greater patient safety, lengthening control, and convenience; this results in a better patient and cost outcomes. The implantable Synoste Nitinail guarantees patients safer treatment, less infections, and less pain. Synoste means a faster return to work and regaining your quality of life quality.

Press releases

Press
21. October 2020

Successful exit for High-Tech Gründerfonds and Evonik Venture Capital – Synoste Oy becomes part of Globus Medical

Globus Medical, based in Audubon, Pennsylvania, USA, is a leading medical device manufacturerThe Finnish start-up Synoste, with offices in Helsinki and Düsseldorf, develops high-tech implants for minimally invasive treatment of leg length discrepancyThe transaction marks HTGF’s 11th successful exit during the coronavirus crisis High-Tech Gründerfonds (HTGF) and Evonik Venture Capital have exited Finnish start-up Synoste Oy. US based Globus Medical (NYSE: GMED) acquired all shares. Hig
 
Press
18. October 2018
SYNOSTE Ltd raises €5.1 million to launch its smart skeletal deformation correction technology
SYNOSTE Ltd, a Finnish medical device company creates smart solutions for patient-friendly bone-lengthening and bone-deformation correction. The company, also located in Düsseldorf, Germany has raised over five million euros to start clinical investigations and to develop new clinical applications. SYNOSTE’s patented technology platform provides the basis for further disruptive changes in the treatment of congenital, trauma- and tumour-related limb discrepancies, adult and paediatric deformit
 
Press
21. January 2016
Venture Capital: Evonik invests in SYNOSTE, a medical technology start-up in Düsseldorf and Helsinki
High-tech implant will make leg-lengthening treatment easier and less painful New medical application with high performance polymer VESTAKEEP® PEEK from Evonik Technology estimated to be available on the market in 2017 Evonik Industries has invested in the start-up company SYNOSTE Oy via its venture capital arm and now holds a minority share in the medical technology company based in Düsseldorf (Germany) and Helsinki (Finland). The investment was made as part of a series A round,
 
Press
6. May 2015
Synoste Oy raises € 2.2 M in the first closing of A-round financing to acquire CE-approval for a next generation implant for correcting skeletal deformities
Synoste Oy, a Finnish medical device company is developing a next-generation of patient friendly implants for the correction of skeletal deformations. Synoste’s proprietary technology will act as a platform for a range of long and short bone, spinal, and craniomaxilofacial applications providing solutions for millions of patients and their families across the globe. Synoste has now raised A-round financing of € 1.2 M which will be used to fund clinical trials needed for regulatory approva
 
Press
14. November 2013
Synoste Oy raises € 2.8 M in financing to Develop Next-Generation implants for correcting skeletal deformities
Synoste Oy, a Helsinki and Düsseldorf based medical device company is developing next-generation implantable devices based on their unique and proprietary technology platform. The company has now raised a seed-round of € 0.8 M to advance the development of its first product aimed at the limb lengthening market. The seed round can be increased up to € 1.2 M upon reaching certain milestones and is supported by TEKES research funding with additional approx. € 1.6 M.  High-Tech Gründerfonds
 

Info & Contact

Harri Halilla
Web:
synoste.com

Address

Brunnenstraße 23
40223 Düsseldorf

In portfolio

11. Nov 2013 – 27. May 2020

HTGF Manager

 
Kay G. Balster, Principal / Authorized signatory
Exit